Peptide Initiative

Peptides · Peptide comparison

Pidotimod vs Thymosin Alpha-1

Synthetic dipeptide immunomodulator that enhances both innate and adaptive immunity through Toll-like receptor activation

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangePidotimod800–800 mgThymosin Alpha-11.6–1.6 mg
FrequencyPidotimodMultiple times dailyThymosin Alpha-1Twice weekly
AdministrationPidotimodOral (tablet)Thymosin Alpha-1Subcutaneous injection
Cycle lengthPidotimod12+ weeksThymosin Alpha-18-12 weeks
Onset speedPidotimodModerate (1-2 weeks)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelPidotimodModerate human trials (Phase 1-2)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Immune

Pidotimod95%
Thymosin Alpha-1No recorded rating

Healing & Recovery

Pidotimod65%
Thymosin Alpha-1No recorded rating

Anti-Aging

Pidotimod45%
Thymosin Alpha-1No recorded rating

Immune Activation

PidotimodNo recorded rating
Thymosin Alpha-195%

Infection Fighting

PidotimodNo recorded rating
Thymosin Alpha-192%

Immune Balance

PidotimodNo recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Pidotimod

Molecular formula
C9H12N2O4S
Molecular weight
244.27 g/mol
Half-life
Approximately 4 hours
Bioavailability
~45% (oral)
CAS number
121808-62-6

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Pidotimod

Oral

  • 400 mg (pediatric, age >3 yr): twice daily for acute infection, once daily for preventionTwice daily (acute) or once daily (prevention) · 15-20 days acute; up to 60 days for preventionApproved pediatric dosing (Italy/Asia; not FDA-approved). Take 2 hours before or after food to preserve absorption. [2][6]
  • 800 mg (adults): twice daily for acute infection, once daily for preventionTwice daily (acute) or once daily (prevention/maintenance) · 8-15 days acute; up to ~60 days for prophylaxisStandard adult dosing for acute respiratory infection with antibiotics, then once-daily maintenance. Take away from meals. [5][6]

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Pidotimod

Recurrent Respiratory Infections
Pidotimod is specifically indicated and most widely studied for preventing recurrent respiratory tract infections (RRTIs), particularly in children over 3 years. Multiple clinical studies and a Phase 4 trial with 338 children have demonstrated significant reductions in infection frequency and duration.
Immunocompromised Patients
Patients with documented cell-mediated immunodepression, including those with HIV or the elderly with weakened immune function, may benefit from pidotimod's ability to enhance T-cell function and rebalance cytokine production.
Seasonal Immune Support
Preventive courses before cold and flu season can strengthen immune defenses through TLR activation and enhanced mucosal immunity (increased salivary IgA), reducing susceptibility to viral respiratory infections.
Chronic Respiratory Conditions
Patients with chronic bronchitis, bronchiectasis, or COPD who experience frequent exacerbations may benefit from pidotimod as an adjunctive therapy to reduce infection-triggered flares.

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Pidotimod

Common

  • Gastrointestinal discomfort
  • Skin rash
  • Headache
  • Nausea
  • Diarrhea
  • Transient fever

Uncommon

  • Allergic reaction

Serious

  • Severe hypersensitivity reaction

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Pidotimod

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Pidotimod (immuno-stimulating dipeptide analog) has 40+ years of safety data in European/Asian markets with favorable tolerability profile. Mild gastrointestinal effects occur in <5% of users; no serious adverse events in 25 years of clinical use across 50,000+ patient population. Oral bioavailability excellent with rapid intestinal absorption. No mutagenicity or carcinogenicity in preclinical testing; immunomodulatory mechanism carries theoretical risk in severely immunocompromised patients.

Contraindications

  • Known hypersensitivity to pidotimod or any excipients
  • Pregnancy and breastfeeding (insufficient safety data)
  • Children under 3 years of age
  • Severe autoimmune disease in active flare

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Pidotimod

Choose Pidotimod if…

  • Preventing recurrent respiratory tract infections
  • Supporting immune function in immunocompromised individuals
  • Reducing frequency of infections in children and elderly
  • Immune support during HIV management

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support